Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
Sight Sciences (Nasdaq: SGHT), an eyecare technology company, announced its participation in the Morgan Stanley Global Healthcare Conference in New York. The company's management will deliver a presentation on Wednesday, September 10, 2025, at 10:50 am PT / 1:50 pm ET.
Investors and interested parties can access both the live and archived versions of the fireside chat through the "Investors" section on the company's website at investors.sightsciences.com.
Sight Sciences (Nasdaq: SGHT), azienda di tecnologie per la cura degli occhi, ha annunciato la sua partecipazione alla Morgan Stanley Global Healthcare Conference a New York. La direzione terrà una presentazione mercoledì 10 settembre 2025 alle 10:50 PT / 13:50 ET.
Investitori e interessati possono seguire la diretta e rivedere la registrazione della conversazione nella sezione "Investors" del sito aziendale all'indirizzo investors.sightsciences.com.
Sight Sciences (Nasdaq: SGHT), una empresa de tecnología oftalmológica, anunció su participación en la Morgan Stanley Global Healthcare Conference en Nueva York. La dirección realizará una presentación el miércoles 10 de septiembre de 2025 a las 10:50 PT / 13:50 ET.
Los inversores y las personas interesadas podrán acceder tanto a la transmisión en directo como a la versión archivada del diálogo a través de la sección "Investors" en la web de la compañía: investors.sightsciences.com.
Sight Sciences (Nasdaq: SGHT)는 안과 의료 기술 회사로, 뉴욕에서 열리는 Morgan Stanley Global Healthcare Conference에 참가한다고 발표했습니다. 회사 경영진은 2025년 9월 10일 수요일 오전 10:50 PT / 오후 1:50 ET에 프레젠테이션을 진행합니다.
투자자 및 관심 있는 분들은 회사 웹사이트의 "Investors" 섹션인 investors.sightsciences.com에서 라이브 및 녹화된 fireside chat을 보실 수 있습니다.
Sight Sciences (Nasdaq: SGHT), une entreprise de technologies ophtalmiques, a annoncé sa participation à la Morgan Stanley Global Healthcare Conference à New York. La direction donnera une présentation le mercredi 10 septembre 2025 à 10h50 PT / 13h50 ET.
Les investisseurs et les personnes intéressées peuvent accéder à la diffusion en direct ainsi qu'à l'enregistrement du fireside chat via la rubrique "Investors" du site web de l'entreprise à l'adresse investors.sightsciences.com.
Sight Sciences (Nasdaq: SGHT), ein Unternehmen für Augenheilkunde-Technologie, hat seine Teilnahme an der Morgan Stanley Global Healthcare Conference in New York angekündigt. Das Management des Unternehmens wird am Mittwoch, 10. September 2025, um 10:50 PT / 13:50 ET eine Präsentation halten.
Investoren und Interessierte können sowohl die Live-Übertragung als auch die Archivaufzeichnung des Fireside-Chats über den Bereich "Investors" auf der Unternehmenswebsite investors.sightsciences.com abrufen.
- None.
- None.
MENLO PARK, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
Sight Sciences’ management is scheduled to present on Wednesday, September 10, 2025, at 10:50 am PT / 1:50 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the Company’s website at: investors.sightsciences.com.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease.
Visit www.sightsciences.com for more information.
Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2025 Sight Sciences. All rights reserved.
Media contact
pr@SightSciences.com
Investor contact
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
FAQ
When is Sight Sciences (SGHT) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors access Sight Sciences' (SGHT) Morgan Stanley conference presentation?
What type of company is Sight Sciences (SGHT)?
Where is the Morgan Stanley Global Healthcare Conference 2025 being held?
